Severe TKI–related clinical toxicities = bette survival

[Olga]

Medical team from Rouen University Hospital in France has found, that in a studies group of the patients with the RCC clinical TKI–related severe toxicities were associated with better survival, so if you are on a trial or under the treatment with one of these TKI drugs (cediranib, sunitinib, sorafenib, pazopanib etc) - do not be discouraged by the severe side effects, because it might be the sign that the drug is effective for you.
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
http://www.nature.com/bjc/journal/vaop/ ... 1507a.html